Targeted vaccination and intrinsic adjuvant function: Next generation checkpoint control

Targeted vaccination and intrinsic adjuvant function: Next generation checkpoint control

21^st World Congress and Exhibition on Vaccines, Vaccination & Immunization
November 09-10, 2017 Vienna, Austria

Geert C Mudde

OncoQR ML GmbH, Austria

Abstract:

Using the S-TIR™ technology platform for human specific therapeutic vaccines OncoQR ML has developed two prototype vaccines for treatment of pancreatic cancer (TYG100) and breast cancer (OQR200). Vaccines derived from this platform consist of 2 modules, the disease specific module, “immunogen” and the generic module, “warhead”, which directs the vaccines to CD32 on antigen presenting cells, especially pDCs and B cells. The immunogen in oncology is a tumor associate auto-antigen, against which under normal conditions no Clinically relevant immune responses can be induced. However, in combination with the warhead, thanks to intrinsic check point control, the immune system generates very strong and rapid antibody and T cell immune responses. The responses are reversible and boostable, thus allowing fine-tuning of the clinical responses on a patient to patient basis. S-TIR™ vaccines in contrast to the current checkpoint inhibitors do not induce autoimmune disease and are tumor specific while mobilizing both arms of the immune system against the tumor.

Biography:

Geert C Mudde received a PhD in Immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/ biotech industry, where he held several senior management positions at the Novartis Research Institute in Vienna, Austria, the Parke Davis Research Institute in Fresnes, France, Ingenium Pharmaceuticals, Martinsried, Germany, and at Igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as Interim Manager, he co-founded the biotech company F-star Biotechnology, where he served as Chief Scientific Officer from 2007 to 2009. In 2009, together with Christof Langer, he started to develop the S-TIR™ technology platform for human specific therapeutic vaccines which led to the foundation of S-TARget therapeutics GmbH in 2010. Since then he serves as CSO and Managing Director for S-TARget therapeutics as well as for the S-TIR™ technology spin-off companies OncoQR ML GmbH and TYG oncology Ltd., which were both founded in 2013

PDF HTML